Login / Signup

Development of a Prototype, Once-Daily, Modified-Release Formulation for the Short Half-Life RIPK1 Inhibitor GSK2982772.

Debra J TompsonMark WhitakerRennan PanGeoffrey S JohnsonTeresa FullerLitza McKenzieVanessa ZannMarcy PowellKathy Abbott-BannerSimon J Hawkins
Published in: Pharmaceutical research (2021)
MT-12 h and MM-12 h provided a QD pharmacokinetic profile in the fasted state, however when MT-12 h was dosed with a high-fat meal a QD profile was not maintained. ( ClinicalTrials.gov Identifier: NCT03266172).
Keyphrases
  • drug delivery
  • physical activity
  • signaling pathway
  • pi k akt